Azenta, Inc. - Common Stock (AZTA)
45.65
+1.79 (4.08%)
NASDAQ · Last Trade: Nov 13th, 5:13 PM EST
News & Press Releases
Why Azenta Stock Crushed it on Wednesdayfool.com
Its final earnings report for fiscal 2026 was impressive.
Via The Motley Fool · November 11, 2026
Azenta (AZTA) Q4 2026 Earnings Call Transcriptfool.com
Management outlines fiscal 2027 targets amid Multiomics headwinds.
Via The Motley Fool · November 11, 2026
What Azenta (AZTA) Said on Its Q4 Earnings Callmarketbeat.com
Azenta (NASDAQ:AZTA) forecast faster organic revenue growth and higher profitability for fiscal 2027 after fourth-quarter sales exceeded expectations, as the company works to improve its automated storage business and expand its gene synthesis capabilities.
The life sciences services company report
Via MarketBeat · November 11, 2026
Azenta (NASDAQ:AZTA) Q4 Earnings Beat Revenue and EPS Consensus, Shares Rise After Hourschartmill.com
Via Chartmill · November 10, 2026
Insider Buying Signals: 3 Healthcare Stocks to Watchinvestorplace.com
Insider buying and share buybacks have put Prothena, Rapport Therapeutics and Azenta on the radar. See the catalysts and risks behind each stock.
Via InvestorPlace · November 11, 2026
Azenta (NASDAQ:AZTA) reports upbeat Q3 CY2026, stock jumps 10.3%
Life sciences company Azenta (NASDAQ:AZTA) reported calendar Q3 2026 (fiscal Q4 2026) results topping the market’s revenue expectations, with revenue up 5.1%...
Via StockStory · November 10, 2026
Azenta earnings: what to look for from AZTA
Life sciences company Azenta (NASDAQ:AZTA) will be reporting earnings tomorrow after market close. Here’s what to expect. Azenta beat analysts’ revenue expec...
Via StockStory · November 9, 2026
3 Reasons to sell AZTA and 1 stock to buy instead
What a fantastic six months it’s been for Azenta. Shares of the company have skyrocketed 46.2%, hitting $35.57. This was partly due to its solid quarterly re...
Via StockStory · November 2, 2026
3 small-cap stocks we find risky
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
Via StockStory · October 30, 2026
Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Oct. 25, 2026 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · October 25, 2026
Moderna, Progyny, Azenta, Oscar Health, and agilon health Shares Skyrocket, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in rising expectations that midter...
Via StockStory · October 19, 2026
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields r...
Via StockStory · October 16, 2026
Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NY...
Via StockStory · October 15, 2026
2 Volatile Stocks with Promising Prospects and 1 We Ignore
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be...
Via StockStory · October 15, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · October 6, 2026
Q2 Earnings Roundup: UFP Technologies (NASDAQ:UFPT) And The Rest Of The Drug Development Inputs & Services Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how drug development input...
Via StockStory · October 5, 2026
Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via StockStory · September 30, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 29, 2026
Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Azenta, Inc. (NASDAQ: AZTA) resulting from allegations that Azenta may have issued materially misleading business information to the investing public.
By The Rosen Law Firm, P.A. · Via Business Wire · September 26, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 22, 2026
Q2 Rundown: 10x Genomics (NASDAQ:TXG) Vs Other Life Sciences Tools & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via StockStory · September 21, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 15, 2026
Q2 Earnings Review: Drug Development Inputs & Services Stocks Led by Azenta (NASDAQ:AZTA)
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta...
Via StockStory · September 13, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Azenta, Inc. (“Azenta” or the “Company”) (NASDAQ: AZTA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · September 8, 2026
Q2 Earnings Highlights: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via StockStory · September 7, 2026